Technical Analysis for GILD - Gilead Sciences, Inc.

Grade Last Price % Change Price Change
C 69.97 1.77% 1.22
GILD closed up 1.77 percent on Thursday, July 11, 2024, on approximately normal volume.
12 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
Multiple of Ten Bearish Other 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
Up 3 Days in a Row Strength 1.77%
Up 4 Days in a Row Strength 1.77%
20 DMA Support Bullish 3.26%
Up 3 Days in a Row Strength 3.26%
Gapped Down Weakness 3.26%

   Recent Intraday Alerts

Alert Time
Up 1 ATR about 20 hours ago
Up 2% about 20 hours ago
10 DMA Support about 21 hours ago
60 Minute Opening Range Breakout about 22 hours ago
Up 1% about 22 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Gilead Sciences, Inc. Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Medicine Biopharmaceutical Nasdaq 100 Disease Inflammation Infection Hypertension Cardiovascular Disease Antibiotics Influenza Coronavirus Vascular Disease Macular Degeneration Liver Disease Pulmonary Arterial Hypertension Respiratory Diseases Cystic Fibrosis HIV Immunodeficiency Oligonucleotide Organic Chemistry Perfusion Hepatotoxins Angina Retinitis Gilead Sciences Prodrugs Treatment Of Cardiovascular Disease Cytomegalovirus Retinitis Fungal Infection Fungal Infections Myocardial Perfusion Imaging Oncology Diseases Tenofovir Disoproxil Treatment Of Cardiovascular Diseases

Is GILD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 85.9057
52 Week Low 61.3181
Average Volume 7,012,429
200-Day Moving Average 72.12
50-Day Moving Average 65.83
20-Day Moving Average 67.47
10-Day Moving Average 68.18
Average True Range 1.59
RSI (14) 62.69
ADX 21.65
+DI 35.50
-DI 22.07
Chandelier Exit (Long, 3 ATRs) 67.41
Chandelier Exit (Short, 3 ATRs) 67.46
Upper Bollinger Bands 72.30
Lower Bollinger Band 62.64
Percent B (%b) 0.76
BandWidth 14.31
MACD Line 0.86
MACD Signal Line 0.78
MACD Histogram 0.0711
Fundamentals Value
Market Cap 87.19 Billion
Num Shares 1.25 Billion
EPS 4.50
Price-to-Earnings (P/E) Ratio 15.55
Price-to-Sales 3.39
Price-to-Book 4.04
PEG Ratio 0.42
Dividend 3.00
Dividend Yield 4.29%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 73.17
Resistance 3 (R3) 72.92 71.61 72.64
Resistance 2 (R2) 71.61 70.79 71.73 72.46
Resistance 1 (R1) 70.79 70.29 71.20 71.04 72.28
Pivot Point 69.47 69.47 69.68 69.60 69.47
Support 1 (S1) 68.65 68.66 69.06 68.90 67.66
Support 2 (S2) 67.34 68.15 67.46 67.48
Support 3 (S3) 66.52 67.34 67.30
Support 4 (S4) 66.77